Liver fibrogenesis is chronic tissue damage characterized by an extracellular accumulation of fibrillar matrix associated with continuous degradation and remodelling. This scientific review describes current concepts on the pathophysiology of liver fibrosis, inflammation as a fundamental concept of liver fibrosis, mechanistic concepts of liver fibrosis, the role of mesenchymal stem cells (MSC) in liver injury, the functional effects of MSC secretome, the advantages of secretome therapy, and the latest research developments on MSC. The role of MSCs has been proven in many liver fibrosis studies involving experimental animals. However, it still requires further research for safety and efficacy aspects
Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterol. 134: 1655–1669.
Wynn TA (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 117: 524–529.
Pinzani M, Macias-Barragan J (2010) Update on the pathophysiology of liver fibrosis. Expert Rev Gastroen-terol Hepatol. 4: 459–472.
Bataller R, Brenner DA (2005) Liver fibrosis. J Clin In-vest. 115: 209–218.
Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 14(7):397–411.
Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A (1994) Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1: 71–81.
Quan TE, Cowper SE, Bucala R (2006) The role of circu-lating fibrocytes in fibrosis. Curr Rheumatol Rep. 8: 145–150.
Pinzani M (2015) Pathophysiology of Liver Fibrosis. Dig Dis. 33:492–497.
Novo E, Parola M (2008) Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair. 1: 5.
De Alwis NMW, Day CP (2008) Non-alcoholic fatty liver: the mist gradually clear. J Hepatol. 48:S105–S112.
Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 14: 181–194.
Machado MV, Cortez-Pinto H (2012) Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol. 11: 440–449.
Olsen Olsen AL, Bloomer SA, Chan EP, Gaça MD, Georges PC, Sackey B, Uemura M, Janmey PA, Wells RG (2011) Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. Am J Physiol Gastro-intest Liver Physiol. 301:G110–G118.
Novo E, Cannito S, Zamara E, et al (2007) Vascular en-dothelial growth factor and angiopoietin-1 as hypoxia-dependent autocrine and paracrine factors stimulating mi-gration and chemotaxis of activated human hepatic stel-late cells. Am J Pathol. 170: 1942–1953.
Chen Y, Choi SS, Michelotti GA, Chan IS, Swiderska-Syn M, Karaca GF, Xie G, Moylan CA, Garibaldi F, Premont R, Suliman HB, Piantadosi CA, Diehl AM (2012) Hedgehog controls hepatic stellate cell fate by regulating metabolism. Gastroenterol. 143: 1319–1329.
Mann DA (2014) Epigenetics in liver disease. Hepatolo-gy. 60: 1418–1425.
Schnabl B, Brenner DA (2014) Interactions between the intestinal microbiome and liver diseases. Gastroenterol. 146: 1513–1524.
Machado MV, Cortez-Pinto H: Gut microbiota and non-alcoholic fatty liver disease. Ann Hepatol 2012; 11: 440–449.
Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol. 4: 499–511.
Otte JM, Rosenberg IM, Podolsky DK (2003) Intestinal myofibroblasts in innate immune responses of the intes-tine. Gastroenterology. 124: 1866–1878.
Coelho AL, Hogaboam CM, Kunkel SL (2005) Chemo-kines provide the sustained inflammatory bridge between innate and acquired immunity. Cytokine Growth Factor Rev. 16: 553–560.
Brun P, Castagliuolo I, Pinzani M, Palu G, Martines D (2005) Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 289:G571–G578.
Brun P, Castagliuolo I, Di Leo V, et al (2007) Increased intestinal permeability in obese mice: new evidences in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 292:G518–G525.
Seki E, Brenner DA (2008) Toll-like receptors and adap-tor molecules in liver disease: update. Hepatology. 48: 322–335.
Olaso E, Ikeda K, Eng FJ, Xu L, Wang LH, et al. (2001). DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J. Clin. Investig. 108:1369–78.
Gressner AM (1995) Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J. Hepatol. 22:28–36.
SchuppanD, Ruehl M, Somasundaram R, Hahn EG (2001) Matrix as a modulator of hepatic fibrogenesis. Semin. Liver Dis. 21:351–72.
Avraamides CJ, Garmy-Susini B, Varner JA (2008) Integ-rins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 8:604–17.
Stupack DG (2007) The biology of integrins. Oncology 21:6–12.
Gay NJ, Symmons MF, Gangloff M, Bryant CE (2014) Assembly and localization of toll-like receptor signalling complexes. Nat Rev Immunol. 14:546–558.
Bryant CE, Symmons M, Gay NJ (2015) Toll-like recep-tor signalling through macromolecular protein complexes. Mol Immunol. 63:162–165.
Luedde T, Kaplowitz N, Schwabe RF (2014) Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterol. 147:765–783.e4.
Weiskirchen R, Tacke F (2016) Liver Fibrosis: From Pathogenesis to Novel Therapies. Dig Dis. 34:410–422.
Rockey DT (1997) he cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatol. 25:2–5.
Seki E, Schwabe RF (2015) Hepatic inflammation and fibrosis: functional links and key pathways. Hepatol. 61:1066–1979.
Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Kotelian-sky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA (2001) Interleukin-13 induces tissue fibro-sis by selectively stimulating and activating transforming growth factor beta (1). J Exp Med. 194: 809-821
Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, Cong M, Iwaisako K, Liu X, Zhang M, Oster-reicher CH, Stickel F, Ley K, Brenner DA, Kisseleva T (2012) Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterol. 143:765-776.e1-e3.
Schuppan D, Kim YO. Evolving therapies for liver fibro-sis. J Clin Invest 2013; 123: 1887-1901.
Gao B, Radaeva S (2013) Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta. 1832: 1061-1069.
Marra F, Aleffi S, Galastri S, Provenzano A (2009) Mon-onuclear cells in liver fibrosis. Semin Immunopathol. 31: 345-358.
Iredale, J.P (2007) Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Investig. 117, 539–548.
Elpek, G.O (2014) Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J. Gastroenterol. 20, 7260–7276.
Zhou, W.C. Zhang, Q.B. Qiao, L (2014) Pathogenesis of liver cirrhosis. World J. Gastroenterol. 20, 7312–7324.
Campana L, Iredale JP (2017) Regression of Liver Fibrosis. Semin. Liver Dis. 37:1–10.
Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, Hartland SN, Snowdon VK, Cappon A, Gordon-Walker TT, et al (2012) Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc. Natl. Acad. Sci.109, E3186–E3195.
Natarajan V, Harris EN, Kidambi S (2017) SECs (Sinusoidal Endothelial Cells), Liver Microenvironment, and Fibrosis. Biomed. Res. Int. 4097205.
Krenkel O, Tacke F (2017) Liver macrophages in tissue homeostasis and disease. Nat. Rev. Immunol. 17:306–321.
Barron L, Wynn TA (2011) Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am. J. Physiol. Gastrointest. Liver Physiol. 300:G723–G728.
Tacke F, Zimmermann HW (2014) Macrophage heterogeneity in liver injury and fibrosis. J. Hepatol. 60, 1090–1096.
Fallowfield JA, Mizuno M, Kendall TJ, Constandinou CM, Benyon RC, Duffield JS, Iredale JP (2007) Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol. 178:5288–5295.
Ying HZ, Chen Q, Zhang WY, Zhang HH, Ma Y, Zhang SZ, Fang J, Yu CH (2017) PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review). Mol. Med. Rep. 16, 7879–7889.
Xu F, Liu C, Zhou D, Zhang L (2016) TGF-beta/SMAD Pathway and Its Regulation in Hepatic Fibrosis. J. Histochem Cytochem 64:157–167.
Nishikawa K, Osawa Y, Kimura K (2018) Wnt/beta-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs. Int. J. Mol. Sci. 19:3103.
Roehlen N, Crouchet E, Baumert TF (2020) Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells. 9: 875.
Wang Y, et al (2016) Liver-derived human mesenchymal stem cells: a novel therapeutic source for liver diseases. Stem Cell Res Ther. 7(1):71.
Liang X. Ding Y. Zhang Y. Tse H.F, Lian, Q (2014) Paracrine mechanisms of mesenchymal stem cell-based therapy: Current status and perspectives. Cell Transplant. 23, 1045–1059.
Driscoll J, Patel T (2019) The mesenchymal stem cell secretome as an acellular regenerative therapy for liver disease. J Gastroenterol. 54:763–773.
58. De Becker A, Riet IV (2016) Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy? World J Stem Cells. 8(3):73–877.
Li W, et al (2012) Mesenchymal stem cells: a double-edged sword in regulating immune responses. i 19(9):1505–13.
Yi T, Song SU (2012) Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res. 35(2):213–21.
Glennie S, et al (2005) Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood.105(7):2821–7.
Jones S, et al (2007) The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol. 179(5):2824–31.
Fouraschen SM, et al (2012) Secreted factors of human liver-derived mesenchymal stem cells promote liver re-generation early after partial hepatectomy. Stem Cells Dev.21(13):2410–9.
Herrera MB, et al (2010) Human liver stem cell-derived microvesicles accelerate hepatic regeneration in hepatec-tomized rats. J Cell Mol Med. 14(6b):1605–18.
Volarevic V, et al (2018) Ethical and safety issues of stem cell-based therapy. Int J Med Sci. 15(1):36–45.
Kurtz A. Mesenchymal stem cell delivery routes and fate. Int J Stem Cells. 2008;1(1):1–7.
Herberts CA, Kwa MS, Hermsen HP (2011) Risk factors in the development of stem cell therapy. J Transl Med. 9:29.
Eggenhofer E, et al (2014) The life and fate of mesen-chymal stem cells. Front Immunol. 5:148.
Parekkadan B, Milwid JM (2010) Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 12:87–117.
Huang XP, et al (2010) Differentiation of allogeneic mes-enchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circula-tion. 122(23):2419–29.
Crop MJ, et al (2010) Human mesenchymal stem cells are susceptible to lysis by CD8(+) T cells and NK cells. Cell Transplant. 20(10):1547–59.
Eom YW, Shim KY, Baik S (2015) Mesenchymal stem cell therapy for liver fibrosis. Korean J Intern Med. 30(5):580-589.
Berardis S, Sattwika PD, Najimi M, Sokal EM (2015) Use of mesenchymal stem cells to treat liver fibrosis: Current situation and future prospects. World J Gastroenterol 21(3):742-758.
Chen L, et al (2008) Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE. 3(4):e1886.
Monsel A, Zhu Y, Gudapati V, Lim H, Lee JW (2016) Mesenchymal Stem Cell Derived Secretome and Extracellular Vesicles for Acute Lung Injury and Other Inflammatory Lung Diseases. Expert Opin Biol Ther. 16(7): 859–871.
D’Arrigo D, Roffi A, Cucchiarini M, Moretti M, Candrian C, Filardo G (2019) Secretome and Extracellular Vesicles as New Biological Therapies for Knee Osteoarthritis: A Systematic Review. J Clin Med. 8(1867)1-16.
Alfaifi M, et al (2018) Mesenchymal stromal cell therapy for liver diseases. J Hepatol. 68(6):1272–85.
Parekkadan B, et al (2007) Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem Biophys Res Commun. 363(2):247–52.
Ramos TL, et al (2016) MSC surface markers (CD44, CD73, and CD90) can identify human MSC-derived extracellular vesicles by conventional flow cytometry. Cell Commun Signal. 14:2.
Kordelas L, et al (2014) MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 28(4):970–3.
An SY, et al (2017) Milk fat globule-EGF factor 8, secreted by mesenchymal stem cells, protects against liver fibrosis in mice. Gastroenterol. 152(5):1174–86.
Yan Y, et al (2017) hucMSC exosome-derived GPX1 is required for the recovery of hepatic oxidant injury. Mol Ther. 25(2):465–79.
Haga H, et al (2017) Extracellular vesicles from bone marrow-derived mesenchymal stem cells improve survival from lethal hepatic failure in mice. Stem Cells Transl Med. 6(4):1262–72.
Beer L, Mildner M, Ankersmit H.J (2017) Cell secretome based drug substances in regenerative medicine: When regulatory affairs meet basic science. Ann. Transl. Med. 5:170.
Eiro N, Sendon-Lago J, Seoane S, Bermudez M.A, Lame-las M.L, Garcia-Caballero T, Schneider J, Perez-Fernandez R. Vizoso F.J (2014) Potential therapeutic ef-fect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells. Oncotarget. 5:10692–10708.
Bermudez M.A, Sendon-Lago J, Eiro N, Trevino M, Gonzalez F, Yebra-Pimentel E, Giraldez M.J, Macia M, Lamelas M.L, Saa J. et al (2015) Corneal epithelial wound healing and bactericidal effect of conditioned me-dium from human uterine cervical stem cells. Invest. Ophthalmol. Vis. Sci. 56: 983–992.
Bermudez M.A, Sendon-Lago J, Seoane S, Eiro N, Gon-zalez, F, Saa, J, Vizoso F, Perez-Fernandez R (2016) An-ti-inflammatory effect of conditioned medium from hu-man uterine cervical stem cells in uveitis. Exp. Eye Res. 149:84–92.
Osugi M, Katagiri W, Yoshimi R, Inukai T, Hibi H, Ueda M (2012) Conditioned media from mesenchymal stem cells enhanced bone regeneration in rat calvarial bone de-fects. Tissue Eng. Part A. 18:1479–1489.
Van Poll D, et al (2008) Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and re-generation in vitro and in vivo. Hepatol. 47(5):1634–43.
Gazdic M, et al (2018) Crosstalk between mesenchymal stem cells and T regulatory cells is crucially important for the attenuation of acute liver injury. Liver Transpl. 24(5):687–702.
Xu X, et al (2017) Mesenchymal stem cell conditioned medium alleviates oxidative stress injury induced by hy-drogen peroxide via regulating miR143 and its target pro-tein in hepatocytes. BMC Immunol. 18(1):51.
Huang B, et al (2016) Mesenchymal stem cells and their secreted molecules predominantly ameliorate fulminant hepatic failure and chronic liver fibrosis in mice respec-tively. J Transl Med. 14:45.
Azhdari Tafti Z, et al. Conditioned media derived from human adipose tissue mesenchymal stromal cells improves primary hepatocyte maintenance. Cell J. 2018;20(3):377–87.
Zhang S, et al (2012) Human umbilical cord matrix stem cells efficiently rescue acute liver failure through paracrine effects rather than hepatic differentiation. Tissue Eng Part A.18(13–14):1352–64.
Lee SC, et al (2015) Lipopolysaccharide preconditioning of adipose derived stem cells improves liver-regenerating activity of the secretome. Stem Cell Res Ther. 6:75.
Guideline on risk management systems for medical products for human use, EMEA/CHMP/96268/2005. [http://www.ema.europa.eu].
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2021 Galaxy Sciences